Endo, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology.
It is involved in developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others that are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty.
The company offers ADRENALIN, a non-selective alpha and beta adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and APLISOL, a sterile aqueous solution of a purified protein derivative for intradermal administration for aid in the diagnosis of tuberculosis.
In addition, it offers SUPPRELIN LA, a soft flexible 12-month hydrogel implant based on hydrogel polymer technology that delivers histrelin acetate, a gonadotropin-releasing hormone agonist, and is indicated for the treatment of CPP in children; AVEED, a novel long-acting testosterone undecanoate for injection for the treatment of hypogonadism; TESTOPEL, a unique, long-acting implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX, a penile injection used to treat erectile dysfunction caused by conditions affecting nerves, blood vessels, emotions, and/or a combination of factors.
It provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays. The company was founded in 1997 and is headquartered in Malvern, Pennsylvania.
